Low-dose rasburicase in hematologic malignancies.

Objective: To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies.

Methods: This study is a retrospective analysis of data on 41 children with hematologic malignacies with laboratory evidence of tumor lysis syndrome (TLS) or clinical features indicating high risk for developing TLS. Patients were treated with rasburicase in doses of 0.